- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS, ciforadenant (CPI-444) / Corvus Pharma
Enrollment closed, Metastases: Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. (clinicaltrials.gov) - Mar 5, 2024 P1/2, N=24, Active, not recruiting, Currently, CBO421 is being advanced as a clinical development candidate for the treatment of solid cancers. Recruiting --> Active, not recruiting
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS, ciforadenant (CPI-444) / Corvus Pharma
Enrollment open, Metastases: Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. (clinicaltrials.gov) - Feb 29, 2024 P1/2, N=24, Recruiting, Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS, ciforadenant (CPI-444) / Corvus Pharma
Enrollment closed, Phase classification, Enrollment change, Metastases: Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. (clinicaltrials.gov) - Feb 13, 2024 P1/2, N=24, Active, not recruiting, N=470 --> 675 | Trial completion date: Nov 2026 --> Sep 2027 | Trial primary completion date: Aug 2025 --> Jun 2026 Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1/2 | N=15 --> 24
- |||||||||| mupadolimab (CPI-006) / Corvus Pharma, ciforadenant (CPI-444) / Corvus Pharma
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (clinicaltrials.gov) - Dec 21, 2023 P1, N=117, Completed, Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1/2 | N=15 --> 24 Active, not recruiting --> Completed | N=378 --> 117 | Trial completion date: Dec 2025 --> Feb 2023 | Trial primary completion date: Dec 2023 --> Dec 2022
- |||||||||| A novel antagonist monoclonal antibody against human adenosine receptor 2a (A2aR) for cancer immunotherapies (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_834;
Furthermore, it showed significant synergistic effect on inhibiting tumor growth when combined with Ipilimumab, Opdivo or Avastin, through multiple mechanisms including reduced ratios of Tregs:CD8+ T cells within the tumor microenvironment. Conclusions The antagonist A2aR antibody represents a promising novel therapeutic candidate to potentiate combinatorial approaches for cancer immunotherapy via enhancing anti-tumor responses in solid tumors that only partially respond or are completely resistance to ICB therapies due to elevated adenosine level in tumor microenvironment.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS, ciforadenant (CPI-444) / Corvus Pharma
Enrollment open, Metastases: Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. (clinicaltrials.gov) - Feb 13, 2023 P1b/2, N=15, Recruiting, A phase I trial for humans with AD is planned. Not yet recruiting --> Recruiting
- |||||||||| CPI-818 / Corvus Pharma
ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_5798; CPI-818 is a covalent inhibitor of ITK (KD 2.5nM) with > 100 fold selectivity over RLK and other TEC family kinases...The increases in Th1 cells and TEMRA CD8+ cells suggest that anti-tumor activity is due to induction of a host anti-tumor response. This raises the possibility that immunomodulation with ITK blockade could be used for immunotherapy of other cancers.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS, ciforadenant (CPI-444) / Corvus Pharma
Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma () - Oct 8, 2022 - Abstract #KCRS2022KCRS_53; Exploratory objectives include assessing gene expression signatures and pharmacodynamic parameters with outcome. Results n/a Conclusions n/a Keywords: adenosine, metabolism, first-line, immunotherapy
- |||||||||| mupadolimab (CPI-006) / Corvus Pharma, ciforadenant (CPI-444) / Corvus Pharma
Enrollment closed, Combination therapy, Metastases: CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (clinicaltrials.gov) - Aug 3, 2022 P1, N=378, Active, not recruiting, Together, this study demonstrated the advantage of GO-PEG mediated combined delivery of CPI444 and vatalanib drugs with increased permeability, a three-pronged combinatorial strategy toward effective GBM treatment. Recruiting --> Active, not recruiting
- |||||||||| ciforadenant (CPI-444) / Corvus Pharma
Journal, Epigenetic controller: Dual-acting antitumor agents targeting the A adenosine receptor and histone deacetylases: Design and synthesis of 4-(furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine derivatives. (Pubmed Central) - May 18, 2022 Based on the core structures of the AAR antagonists V-2006 and CPI-444, novel 4-(furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine derivatives were designed as such dual-acting compounds...Compounds with balanced AAR antagonism and HDAC inhibition were tested for their in vitro anti-proliferative activity and pharmacokinetic properties. One of the compounds, 14c (4-(2-(6-Amino-4-(furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-N-(2-amino-phenyl)benzamide) showed an overall favorable pharmacokinetic profile; in the mouse MC38 xenograft model, it showed potent anti-tumor effects with inhibition rates of 44% (90 mg/kg, po, bid) and 85% (60 mg/kg, ip, bid), respectively.
- |||||||||| mupadolimab (CPI-006) / Corvus Pharma, ciforadenant (CPI-444) / Corvus Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (clinicaltrials.gov) - Apr 15, 2022 P1, N=378, Recruiting, One of the compounds, 14c (4-(2-(6-Amino-4-(furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-N-(2-amino-phenyl)benzamide) showed an overall favorable pharmacokinetic profile; in the mouse MC38 xenograft model, it showed potent anti-tumor effects with inhibition rates of 44% (90 mg/kg, po, bid) and 85% (60 mg/kg, ip, bid), respectively. Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Mar 2022 --> Dec 2023
- |||||||||| Talzenna (talazoparib) / Pfizer, Welireg (belzutifan) / Merck (MSD), ciforadenant (CPI-444) / Corvus Pharma
Retrospective data, Review, Journal, PARP Biomarker, IO biomarker: Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations. (Pubmed Central) - Apr 8, 2022 The first-line regimen, and the type and duration of response emerged as crucial factors that could influence the efficacy of second-line therapy. Prognostic models that integrate clinical features and molecular biomarkers with a predictive value are warranted to guide clinicians in the decision-making process with the ultimate goal of offering to the patients the most effective therapy in a personalized, precision medicine-based, therapeutic strategy.
- |||||||||| ciforadenant (CPI-444) / Corvus Pharma
Trial completion, Trial completion date, Combination therapy: Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 11, 2022 P1, N=7, Completed, Prognostic models that integrate clinical features and molecular biomarkers with a predictive value are warranted to guide clinicians in the decision-making process with the ultimate goal of offering to the patients the most effective therapy in a personalized, precision medicine-based, therapeutic strategy. Active, not recruiting --> Completed | Trial completion date: Nov 2021 --> Mar 2022
- |||||||||| soquelitinib (CPI-818) / Corvus Pharma
Trial completion date, Trial primary completion date: A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma (clinicaltrials.gov) - Feb 9, 2022 P1, N=151, Recruiting, Trial completion date: Nov 2023 --> Aug 2025 | Trial primary completion date: Feb 2022 --> Apr 2024 Trial completion date: Dec 2022 --> Apr 2026 | Trial primary completion date: Dec 2021 --> Apr 2026
- |||||||||| CPI-818 / Corvus Pharma
Highly Selective Irreversible ITK Inhibitor Cpi-818 Reduces Acute Graft-Versus Host Disease (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_5511; P1 Conclusion These data in two clinically relevant GVHD models demonstrate that ITK inhibition has potential as a novel targeted approach to prevent aGVHD through a) the suppression of T cell activation and proliferation, b) decreased concentrations of pro-inflammatory cytokines and increased concentration of anti-inflammatory cytokines. CPI-818 is the most potent and selective ITK inhibitor reported to date and these data highlight its promise as a novel agent for the prevention of aGVHD.
- |||||||||| ciforadenant (CPI-444) / Corvus Pharma
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 3, 2021 P1, N=7, Active, not recruiting, CPI-818 is the most potent and selective ITK inhibitor reported to date and these data highlight its promise as a novel agent for the prevention of aGVHD. Recruiting --> Active, not recruiting | N=28 --> 7 | Trial completion date: Jul 2025 --> Nov 2021 | Trial primary completion date: Feb 2023 --> Sep 2021
- |||||||||| AK119 / Akesobio
AK119, A CD73 Targeting Antibody with Dual Mechanism of Action (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_1099; The in-vivo activity of AK119 was further studied in bleomycin-induced pulmonary fibrosis model in human CD73 transgenic mouse...AK119 show significantly higher bioactivity to induce B cells activation in comparison with MEDI9447 or CPI006 (figure 4)...Results from non-clinical pharmacology studies reveal potent bioactivities as well as favorable safety properties of AK119. AK119 is intended for advanced solid tumors, pulmonary fibrosis and therapy of COVID-19.
- |||||||||| mupadolimab (CPI-006) / Corvus Pharma
Enrollment closed, Enrollment change, Trial primary completion date: Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients (clinicaltrials.gov) - Jun 15, 2021 P1, N=30, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Jul 2021 --> Mar 2021 Recruiting --> Active, not recruiting | N=70 --> 30 | Trial primary completion date: Mar 2021 --> Jul 2021
- |||||||||| mupadolimab (CPI-006) / Corvus Pharma
Enrollment change: Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients (clinicaltrials.gov) - Oct 19, 2020 P1, N=60, Recruiting, Further, our data suggests that blocking TCR signaling by targeting ITK may be an effective strategy for treating adult and pediatric ALPS. N=30 --> 60
|